RESUMEN
Transverse myelitis and cerebral venous thrombosis represent some of the described neurological complications of coronavirus disease. A woman in her early 30s presented with headache, left-sided sensory symptoms and voiding difficulty. The patient also reported dry cough, fever, nasal congestion, anosmia and ageusia 2 weeks before presentation. The clinical examination showed sensory disturbances on the left side of the body, starting from the lower abdomen and extending to the left leg, which was consistent with transverse myelitis. The laboratory assessment confirmed a previous infection with coronavirus disease and excluded autoimmune entities. Radiological investigations revealed left transverse sinus thrombosis with no spinal cord abnormalities. The treatment was started with therapeutic anticoagulation and intravenous high-dose steroids. The patient showed significant improvement, and the neurological deficits resolved after 3 months. This is the first documented case of imaging-negative myelitis associated with cerebral venous thrombosis after coronavirus disease.
Asunto(s)
COVID-19 , Trombosis Intracraneal , Mielitis Transversa , Trombosis de la Vena , Femenino , Humanos , COVID-19/complicaciones , Mielitis Transversa/diagnóstico por imagen , Mielitis Transversa/tratamiento farmacológico , Trombosis Intracraneal/diagnóstico por imagen , Trombosis Intracraneal/tratamiento farmacológico , Trombosis Intracraneal/etiología , Imagen por Resonancia Magnética , Trombosis de la Vena/diagnóstico por imagen , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/etiologíaRESUMEN
BACKGROUND: Despite a considerable number of articles regarding neurological manifestations associated with severe acute respiratory syndrome coronavirus 2 infection, reports on transverse myelitis and encephalitis are scarce. CASE PRESENTATION: We report a 35-year-old Asian Arab female presenting with longitudinally extensive transverse myelitis within 3 weeks after being diagnosed with mild coronavirus disease 2019 infection. Administration of high-dose methylprednisolone led to significant clinical improvement. However, 2 days after discharge, the patient was readmitted with encephalitis manifestations, consisting of fever and loss of consciousness, along with deterioration in myelitis symptoms. Severe acute respiratory syndrome coronavirus 2 antibody was detected in cerebrospinal fluid, but DNA of severe acute respiratory syndrome coronavirus 2 was not found. Clinical recovery was achieved after the administration of intravenous immunoglobulin. CONCLUSION: Longitudinally extensive transverse myelitis can be a neurological manifestation of coronavirus disease 2019 and can be followed by encephalomyelitis episodes. High-dose steroids and intravenous immunoglobulin as an immunomodulator are possible effective treatment options.
Asunto(s)
COVID-19 , Encefalitis , Encefalomielitis , Mielitis Transversa , Adulto , COVID-19/complicaciones , Encefalomielitis/complicaciones , Femenino , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Mielitis Transversa/tratamiento farmacológicoRESUMEN
There are increasing reports of immune-mediated and para-infectious syndromes beyond the well-known respiratory manifestations of severe-acute-respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the spectrum of severe neurological sequelae of SARS-CoV-2 remains undefined. We present the case of a 66-year-old female with rapidly progressive lower limb neurology 3 days post SARS-CoV-2 infection. Clinical and radiological findings were in keeping with transverse myelitis and treatment success was achieved with methylprednisolone and remdesivir. This report will discuss the associations between SARS-CoV-2 and acute transverse myelitis. We believe this is one of few described cases of early SARS-CoV-2-associated transverse myelitis secondary to neurotropism and the first successfully treated with the inclusion of remdesivir in the therapeutic regimen.
Asunto(s)
COVID-19 , Mielitis Transversa , Anciano , COVID-19/complicaciones , Femenino , Humanos , Metilprednisolona/uso terapéutico , Mielitis Transversa/tratamiento farmacológico , Mielitis Transversa/etiología , SARS-CoV-2RESUMEN
Acute transverse myelitis (ATM) has been reported as rare complication of vaccination. Herein, we report 2 cases of ATM after the administration of an mRNA vaccine for coronavirus disease 2019 (COVID-19). The first one is an 81-year-old man who received the BNT162b2 vaccine. He presented with bilateral hand weakness. Spine magnetic resonance imaging (MRI) showed high signal intensity from the C1 to C3 vertebrae. The second is a 23-year-old woman who received the BNT162b2 vaccine and experienced tingling in her legs. Spine MRI showed a high signal intensity lesion at the conus medullaris. These patients were treated with intravenous methylprednisolone and their symptoms improved slightly. Careful follow-up is needed to identify adverse events after the administration of mRNA vaccines for COVID-19.
Asunto(s)
Vacuna BNT162/efectos adversos , Mano/fisiopatología , Pierna/fisiopatología , Mielitis Transversa/patología , Médula Espinal/fisiopatología , Vacunación/efectos adversos , Anciano de 80 o más Años , Vacuna BNT162/inmunología , COVID-19/inmunología , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Metilprednisolona/uso terapéutico , Mielitis Transversa/diagnóstico , Mielitis Transversa/tratamiento farmacológico , SARS-CoV-2/inmunología , Columna Vertebral/diagnóstico por imagen , Adulto JovenRESUMEN
Acute disseminated encephalomyelitis (AEM) and acute transverse myelitis (OPM) are autoimmune demyelinating diseases of the central nervous system. Two clinical observations of AEM and OPM developed after suffering acute coronavirus infection (SARS-CoV-2) are presented. Differential diagnosis was carried out with multiple sclerosis, encephalitis of an infectious nature, compressive myelopathy, and opticomyelitis. Both observations show an almost complete recovery of lost functions. The pathogenetic mechanisms of the development of AEM and OPM in patients with coronavirus infection are discussed. The onset of central nervous system dysimmune lesion in the context of coronavirus infection makes it necessary to monitor the clinical situation with the involvement of a neurologist for timely diagnosis and determination of therapeutic tactics that can reduce the degree of disability of patients.
Asunto(s)
COVID-19 , Encefalomielitis Aguda Diseminada , Mielitis Transversa , Enfermedades del Sistema Nervioso , Humanos , COVID-19/complicaciones , COVID-19/diagnóstico , Encefalomielitis Aguda Diseminada/diagnóstico , Encefalomielitis Aguda Diseminada/etiología , Encefalomielitis Aguda Diseminada/tratamiento farmacológico , Mielitis Transversa/diagnóstico , Mielitis Transversa/etiología , Mielitis Transversa/tratamiento farmacológico , SARS-CoV-2RESUMEN
Neurological manifestations are common in SARS-CoV-2 infection, including life-threatening acute muscle weakness, due to neuromuscular disorders such as acute transverse myelitis (TM) and Guillain-Barré syndrome (GBS). These syndromes can rarely coexist and present as an overlap syndrome. Here, we report a patient who developed acute symmetrical proximal lower limb weakness 5 days after diagnosis of COVID-19. GBS was diagnosed due to the presence of motor signs, albumin-cytological dissociation in cerebrospinal fluid examination and axonal damage according to nerve condition tests. However, abnormal areas on MRI of the thoracic spine and lack of improvement with intravenous immunoglobulin supported a diagnosis of TM. Therefore, a possible overlap between GBS and TM was established. To our knowledge, this is the third case report of GBS/TM overlap syndrome after COVID-19. The patient's full and rapid recovery with intravenous corticosteroids and plasmapheresis supports our diagnosis.
Asunto(s)
Enfermedades Autoinmunes , COVID-19 , Síndrome de Guillain-Barré , Mielitis Transversa , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Guillain-Barré/tratamiento farmacológico , Humanos , Mielitis Transversa/diagnóstico , Mielitis Transversa/tratamiento farmacológico , Mielitis Transversa/etiología , SARS-CoV-2RESUMEN
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and administered worldwide. There have been reports of neurological adverse events following immunization (AEFIs). We herein report a case of refractory longitudinally extensive transverse myelitis in a 75-year-old Japanese man following the first dose of the BNT162b2 vaccine. The patient developed total sensory loss below the umbilicus and complete paralysis in both legs. Although he was treated with steroid therapy and plasma exchange, his recovery was limited, and severe sequelae remained. Further studies, including large epidemiological studies, are required to understand the association between SARS-CoV-2 vaccines and neurological AEFI.
Asunto(s)
COVID-19 , Mielitis Transversa , Anciano , Vacuna BNT162 , Vacunas contra la COVID-19/efectos adversos , Humanos , Japón , Masculino , Mielitis Transversa/tratamiento farmacológico , Mielitis Transversa/etiología , SARS-CoV-2 , Vacunación/efectos adversosRESUMEN
Longitudinal extensive transverse myelitis (LETM) is a rare but recognised complication of vaccination. We report the case of a 58-year-old man admitted to hospital 10 days after his first AstraZeneca COVID-19 vaccination with progressive neurological symptoms and signs, and investigations and imaging consistent with LETM.This case reviews the literature and the investigative process behind excluding other diagnoses given the patient's background of pulmonary sarcoidosis. It is unique in being the first UK report of a case of LETM with a strong temporal link to COVID-19 vaccination.
Asunto(s)
COVID-19 , Mielitis Transversa , Vacunas contra la COVID-19 , Humanos , Masculino , Persona de Mediana Edad , Mielitis Transversa/inducido químicamente , Mielitis Transversa/tratamiento farmacológico , SARS-CoV-2 , Vacunación/efectos adversosRESUMEN
SARS-COV-2 infection has affected millions of individuals with a wide range of clinical manifestations, including central and peripheral nervous systems through several mechanisms. A rare but potentially severe manifestation of this virus is transverse myelitis. Herein, we report on two patients who developed paraparesis, sensory deficit, and autonomic changes on the tenth day after infection by COVID-19. A 27-year-old man, previously healthy, had symptoms of COVID-19 confirmed by oropharyngeal and nasopharyngeal swab tests. On the tenth day of symptoms, the patient started to experience acute paraparesis, urinary retention, constipation, and hypoesthesia up to the T4 level. The second patient is a 50-year-old man, previously healthy, who had symptoms of the flu-like syndrome. The diagnosis of COVID-19 infection was confirmed by oropharyngeal and nasopharyngeal swab tests. On the tenth day of symptoms, the patient started to experience paraparesis, urinary incontinence, and hypoesthesia up to the T6 level. The neuroimaging and cerebrospinal fluid (CSF) analysis of both patients confirmed acute transverse myelitis after COVID-19 infection. High-dose corticosteroid therapy was started, and both patients showed rapid recovery from their deficits. Although rare, post-infectious transverse myelitis may be related to SARS-COV-2 infection and should be quickly recognized. Although controlled studies are needed, treatment with corticosteroid therapy in high doses was effective in these patients.
Asunto(s)
Corticoesteroides/uso terapéutico , COVID-19/complicaciones , Mielitis Transversa/tratamiento farmacológico , Mielitis Transversa/virología , Adulto , Humanos , Masculino , Persona de Mediana Edad , SARS-CoV-2RESUMEN
COVID-19 infection can cause inflammatory reactions that could involve several organs. In the pediatric population, Multi-System Inflammatory Syndrome in Children (MIS-C) has been reported as one of the consequences of COVID-19. We report a unique pediatric COVID-19 patient with MIS-C, associated with paralysis of the extremities. MRI showed abnormal signal in the cervical spinal cord compatible with transverse myelitis. Methylprednisolone and IVIG were administered, without significant symptom improvement. As a next step, Infliximab was tried for her, and she responded remarkably well to this treatment. Infliximab may be considered as a treatment option in COVID-19 patients with transverse myelitis.
Asunto(s)
COVID-19/complicaciones , Mielitis Transversa/diagnóstico por imagen , Mielitis Transversa/etiología , Síndrome de Respuesta Inflamatoria Sistémica/diagnóstico por imagen , Síndrome de Respuesta Inflamatoria Sistémica/etiología , Antirreumáticos/uso terapéutico , COVID-19/diagnóstico por imagen , COVID-19/etiología , Niño , Femenino , Humanos , Infliximab/uso terapéutico , Mielitis Transversa/tratamiento farmacológico , Síndrome de Respuesta Inflamatoria Sistémica/tratamiento farmacológico , Tratamiento Farmacológico de COVID-19RESUMEN
A 35-year-old woman, 6 months post partum, presented with acute onset back pain at the T8 level progressing to bilateral lower limb weakness and sensory loss with urinary retention and constipation. This patient had a pre-existing inflammatory disease, having recently developed ulcerative colitis antenatally. Five days prior to admission, she had tested positive asymptomatically on a SARS-CoV-2 reverse-transcriptase PCR nasopharyngeal swab. The positive swab result was confirmed on admission. Clinical examination revealed bilaterally exaggerated knee reflexes, lower limb weakness and positive Babinski's sign. Sensation was impaired at L4 and L5 dermatomes and absent at S1 and S2. MRI findings suggested longitudinal extensive transverse myelitis, with multiple regions of patchy hyperintensity seen in the thoracic region of the spinal cord both centrally and peripherally. She was started on a course of intravenous corticosteroids and improvement was seen both clinically and on repeat imaging. This case demonstrates a rare complication to an asymptomatic COVID-19 infection and explores the potential neurotropic properties of COVID-19.
Asunto(s)
COVID-19 , Mielitis Transversa , Adulto , Femenino , Humanos , Imagen por Resonancia Magnética , Mielitis Transversa/diagnóstico , Mielitis Transversa/tratamiento farmacológico , Mielitis Transversa/etiología , SARS-CoV-2RESUMEN
BACKGROUND: Longitudinally extensive transverse myelitis (LETM) is a rare subtype of transverse myelitis (TM) that potentially results in relevant disability. Apart from association to neuromyelitis optica and other chronic demyelinating diseases of the central nervous system, many other aetiologies are known. Particularly systemic infections and vaccination are considered potential triggers for immune mediated inflammation of the spinal cord. In the course of the current Covid-19 pandemic several cases of TM following Covid-19 infection have been described. Here we present a case of LETM following vaccination against Covid-19 with AZD1222, AstraZeneca. An extensive diagnostic work up was performed to rule out alternative causes, including prior and current Covid-19 infection. CONCLUSION: To our knowledge this is first case of LETM possibly related to Covid-19 vaccination that is published after marketing authorisation of various vaccine candidates.
Asunto(s)
Vacunas contra la COVID-19/efectos adversos , Mielitis Transversa/inducido químicamente , Mielitis Transversa/diagnóstico por imagen , Vacunación/efectos adversos , Corticoesteroides/administración & dosificación , Vacunas contra la COVID-19/administración & dosificación , ChAdOx1 nCoV-19 , Humanos , Masculino , Persona de Mediana Edad , Mielitis Transversa/tratamiento farmacológicoRESUMEN
OBJECTIVE: To report a unique case and literature review of post COVID-19 associated transverse myelitis and dysautonomia with abnormal MRI and CSF findings. BACKGROUND: Coronavirus disease have been reported to be associated with several neurological manifestations such as stroke, Guillain-Barré syndrome, meningoencephalitis amongst others. There are only few reported cases of transverse myelitis with the novel coronavirus (n-CoV-2) and only one reported case identifying dysautonomia in COVID-19 patient. Here, we identify a COVID-19 patient diagnosed with acute transverse myelitis in addition to dysautonomia following with complete resolution of symptoms. METHOD: A retrospective chart review of a patient diagnosed with post SARS-CoV-2 infection acute transverse myelitis and dysautonomia, and a review of literature of all the reported cases of transverse myelitis and COVID-19, from December 1st, 2019 till December 25th, 2020, was performed. CONCLUSION: To our knowledge, this is the first reported case of transverse myelitis and dysautonomia in a patient with SARS-CoV-2 infection, who responded to intravenous methyl prednisone and bromocriptine. Follow-up imaging of the spine showed complete resolution of the lesion. Further studies would be recommended to identify the underlying correlation between COVID-19 and transverse myelitis.
Asunto(s)
COVID-19/complicaciones , Mielitis Transversa/virología , Disautonomías Primarias/virología , Médula Espinal/patología , Adulto , Antiinflamatorios/uso terapéutico , Bromocriptina/uso terapéutico , COVID-19/patología , Agonistas de Dopamina/uso terapéutico , Humanos , Masculino , Metilprednisolona/uso terapéutico , Mielitis Transversa/tratamiento farmacológico , Mielitis Transversa/patología , SARS-CoV-2RESUMEN
SARS-CoV-2 has wreaked havoc globally and has claimed innumerable lives all over the world. Apart from the characteristic respiratory illness, this disease has been associated with florid extrapulmonary manifestations and complications. A 59-year-old female healthcare worker presented with features of acute-onset non-compressive myelopathy with a sensory level at T10 segment along with high-grade fever for 4 days. MRI of dorsal spine was suggestive of myelitis at T7 vertebral level. She was initiated on injectable steroids and did show some initial signs of recovery. A day later, she developed an acute-onset respiratory failure but could not be revived despite our best efforts. Her nasopharyngeal and oropharyngeal swab turned out to be positive for SARS-CoV-2 reverse transcriptase polymerase chain reaction (RT-PCR). We hereby report a case of acute transverse myelitis with COVID-19 as a probable aetiology.
Asunto(s)
Infecciones por Coronavirus/complicaciones , Mielitis Transversa/virología , Neumonía Viral/complicaciones , Vértebras Torácicas/virología , Betacoronavirus , COVID-19 , Diagnóstico Diferencial , Resultado Fatal , Femenino , Glucocorticoides/uso terapéutico , Humanos , Metilprednisolona/uso terapéutico , Persona de Mediana Edad , Mielitis Transversa/diagnóstico por imagen , Mielitis Transversa/tratamiento farmacológico , Pandemias , Insuficiencia Respiratoria/virología , SARS-CoV-2 , Vértebras Torácicas/diagnóstico por imagenRESUMEN
A 60-year-old man presented to hospital with bilateral lower limb weakness, urinary retention and constipation. He had been diagnosed with COVID-19 10 days prior. Clinical examination revealed global weakness, increased tone, hyperreflexia and patchy paresthesia in his lower limbs bilaterally. Preliminary blood tests performed revealed a mildly elevated C reactive protein and erythrocyte sedimentation rate but was otherwise unremarkable. MRI scan of his whole spine demonstrated hyperintense T2 signal centrally from T7 to T10, suggestive of acute transverse myelitis. A lumbar puncture showed elevated protein count but normal glucose and white blood cell count. Serological testing for other viruses was negative. His neurological symptoms improved significantly after treatment with intravenous methylprednisone. This case highlights a potential neurological complication of COVID-19 infection.